AstraZeneca has issued a public advisory on the withdrawal of its cholesterol drug Crestor, which it is withdrawing from the market after a study showed it is causing an increased risk of heart attack and stroke.
This follows a recent study by Pfizer that showed the risk of heart attacks and strokes in people taking the cholesterol-lowering medication Crestor had increased by 30 percent compared to people taking a placebo.
Pfizer’s study had found a 44 percent increased risk of developing heart attacks, strokes and other heart conditions in people taking statins like Crestor.
The company, which is in a class of drugs called ‘anti-hypertensive’ drugs, has also issued a public advisory.
Crestor is the first statin to be approved for the treatment of type 2 diabetes and is also known for being a ‘first-line therapy’ for people with heart failure.
The company said it will “remain concerned” that Crestor has increased the risk of cardiovascular events and it is reviewing the information it has received.
Pfizer will continue to sell the drug and will issue a public advisory on the withdrawal.
The news is good news for the company, which is facing an increasing supply of cholesterol-lowering drugs.
It is possible that AstraZeneca’s shares have fallen since the announcement. However, it is important to note that the company has not withdrawn from the market since the announcement.
AstraZeneca shares fell 1 percent on the news on Thursday morning, down 0.3 percent at 09.25 in London. The news has been corrected to close at 09.25.
AstraZeneca shares fell 1 percent on the news on Thursday morning, down 0.3 percent at 09.25.AstraZeneca has withdrawn from the cholesterol-lowering drug Crestor, which it was previously approved for.
The company is due to announce a public advisory on the withdrawal of Crestor in the second half of this year, following the publication of the findings of a study which showed the risk of heart attacks and strokes in people taking the cholesterol-lowering medication Crestor was increasing.
AstraZeneca is one of the world’s biggest drug companies and is one of the biggest manufacturers of cardiovascular drugs.
Pfizer has confirmed the results of the study which showed the risk of heart attacks and strokes in people taking the cholesterol-lowering medication Crestor is increasing.
The company’s research found a 44 percent increased risk of developing heart attacks, strokes and other heart conditions in people taking the cholesterol-lowering medication Crestor.
The company said it will remain concerned about the findings of the study.
It was also asked to update the company on the latest news.
AstraZeneca is one of the world’s biggest drug companies and is one of the largest manufacturers of cardiovascular drugs.
In a trial conducted by the FDA in 2015, AstraZeneca’s blockbuster cholesterol drug Crestor (rosuvastatin) was approved for the treatment of high cholesterol levels in adults. The results of that trial are published today in the journal BMJ Open.
Rosuvastatin has been shown to reduce the risk of strokes in adults, and it is an oral medication approved to treat high cholesterol. It is also known to cause side effects such as muscle pain and fatigue, although it is not considered a controlled drug.
In the trial, Crestor patients had a 40% lower risk of developing heart disease compared with patients who were treated with placebo. However, Crestor patients taking Crestor had a greater risk of developing high-grade cervical cancer.
The trial has shown that Crestor, which is marketed under the brand name Rosuvastatin, can be used safely and effectively in the management of high cholesterol in adults. It is currently in an early stage clinical phase 2 trial and is expected to be approved later this year.
The study involved 977 adults with high cholesterol who were randomly assigned to take Crestor, either as a treatment or a placebo. The primary endpoint of the trial was heart attack and stroke. Secondary endpoints included laboratory blood tests, including total cholesterol, low-density lipoprotein (LDL) cholesterol, and high-density lipoprotein (HDL) cholesterol.
The researchers concluded that, in the primary analysis, the trial showed that Crestor was significantly associated with an increased risk of heart attack and stroke. They concluded that “an increased risk of heart attack and stroke is present with Crestor use.”
According to the study’s results, “Patients taking Crestor may still be protected from cardiovascular events such as cardiovascular death, stroke, myocardial infarction or hospitalisation, with the benefit of cardiovascular protection being greater when taking Crestor compared with placebo.”
In addition, the study’s results also show that there is a “strong evidence that Crestor may be as safe and effective as other lipid-lowering medications.”
The company also said that the trial was “excellent” in terms of quality. The company also said that the findings from the trial “demonstrate the effectiveness of this drug as a primary treatment for patients with high cholesterol who are not currently taking statins.”
Crestor was developed by AstraZeneca and has been sold in the US, Europe and Canada by AstraZeneca.
Crestor: The Crestor Information SheetThe Crestor Information Sheet: Crestor is a cholesterol-lowering medication that is approved for the treatment of high cholesterol in adults.
Crestor: AstraZeneca to market Crestor: AstraZeneca is buying Crestor to market as Crestor, a cholesterol-lowering medication.Crestor, or rosuvastatin, is a cholesterol-reducing medication that is commonly used to treat high cholesterol in adults.
The drug belongs to a class of drugs called statins. These drugs work by decreasing the amount of cholesterol that your body makes, thereby lowering your risk of heart attack and stroke. The drug is also approved to help manage high blood pressure and reduce the risk of stroke and heart failure.
In the study, the researchers looked at the data from patients who had been taking Crestor for at least three months before the trial began. The researchers found that the treatment group had a 40% lower risk of developing high-grade cervical cancer compared with patients who were taking placebo.
They concluded that, “[t]his, a statin, is the most effective and safe treatment for high cholesterol.”
The company is continuing to market Crestor in the US, Europe, Canada, and Australia.
AstraZeneca has received regulatory approval for the drug in the US, Europe, Canada, Japan, and Australia. It is also marketing it in Canada.
The company has received a number of regulatory approvals for its cholesterol-lowering medication, rosuvastatin.
Crestor: Crestor and cholesterol-lowering medication: In the trial, Crestor patients had a 40% lower risk of developing high-grade cervical cancer compared with patients who were taking placebo. The study's results showed that, “Patients taking Crestor may still be protected from cardiovascular events such as cardiovascular death, stroke, myocardial infarction or hospitalisation, with the benefit of cardiovascular protection being greater when taking Crestor compared with placebo.Published:May 31, 2025 8:12 AM MD, FDA
The U. S. Food and Drug Administration (FDA) has issued a warning for the use of the cholesterol drug Crestor, which is sold under the brand name Crestor, by individuals who have suffered adverse events related to taking it and have been prescribed it.
The FDA has issued a warning for the use of Crestor by individuals who have been prescribed the drug in the United States as an adjunct to medical treatment.
Crestor is a member of the statins drug class and is a generic drug. It is marketed under the brand name Crestor by AstraZeneca Pharmaceuticals.
Crestor, sold under the brand name Crestor, is prescribed for individuals who suffer from high cholesterol and for those who have experienced adverse events related to taking it or have been prescribed it as an adjunct to medical treatment.
The FDA has issued an FDA advisory advisory advising that Crestor is not recommended for use in people who have experienced or had side effects related to taking Crestor or other statins.
Additionally, the FDA advisory issued a statement saying that the drug has not been shown to be safe and effective in patients with liver disease or those taking certain other medications. The statement said that the drug has not been approved by the FDA for use in these patients, and that it may cause harmful side effects or adverse events.
Additionally, the FDA advisory said that the FDA has not approved Crestor for patients who have suffered adverse events related to taking a statin. The advisory said that it has not been shown to be effective in patients who have taken statins or other medications to manage cholesterol levels. The advisory said that the FDA has not approved Crestor for patients who have suffered adverse events related to taking statins.
The FDA has issued a statement saying that the drug has not been shown to be effective in patients with liver disease or those taking certain other medications.
Additionally, the FDA said that the FDA has not approved Crestor for patients who have experienced adverse events related to taking a statin. The advisory said that the FDA has not approved Crestor for patients who have suffered adverse events related to taking a statin.
The FDA has issued a warning for the use of the cholesterol drug Crestor, which is sold under the brand name Crestor, by individuals who have suffered adverse events related to taking it and have been prescribed it.
The FDA has issued a warning for the use of the cholesterol drug Crestor, which is sold under the brand name Crestor, by individuals who have suffered adverse events related to taking it and have been prescribed it as an adjunct to medical treatment.
The FDA has issued a warning for the use of the cholesterol drug Crestor, which is sold under the brand name Crestor, by individuals who have experienced or had side effects related to taking it and have been prescribed it as an adjunct to medical treatment.
Rosuvastatin calcium
Consumer Medicine Information
This leaflet answers some of the common questions people ask about CRESTOR. It does not contain all the information that is known about CRESTOR.
It does not take the place of talking to your doctor and pharmacist.
All medicines have risks and benefits. Your doctor will have weighed the risks of you taking CRESTOR against the benefits they expect it will have for you.
If you have any concerns about taking this medicine, ask your doctor or pharmacist.
Keep this leaflet with the medicine.You may need to read it again.
CRESTOR is used to lower high cholesterol levels.
Even though you may have normal cholesterol, CRESTOR can also be used to reduce the risk of some other conditions.
There are two types of cholesterol-lowering agents known as "statins". These lower cholesterol by blocking the production of cholesterol synthesis in the liver.
Thesestatins work by stopping the production of cholesterol in the liver. This helps reduce the amount of cholesterol that the liver does not produce.
Your doctor may also change this information to discuss possible other risk factors you may have.
There is no benefit to taking CRESTOR for high cholesterol in type 2 diabetes mellitus and some cancers including prostate cancer and some types of breast and head and neck cancers.
CRESTOR does not lower your risk of any other related diseases. Your doctor may recommend other medicines or other adjustments to your diet.
Your doctor may not recommend taking CRESTOR if you have any of these conditions:
Your doctor may tell you not to take CRESTOR.
Your doctor may have given you other medicines that would also lower your risk of getting any of the conditions you are having.
Your doctor or pharmacist will be helping to prescribed the right medicines for you.
Do not take CRESTOR if you are pregnant or intend to become pregnant. Your doctor will advise you to use other medicines that will lower your cholesterol levels and therefore reduce your cholesterol-lowering effect. Your doctor may prescribe some other medicines that lower your cholesterol levels but do not affect your baby.
Your doctor may tell you to take other medicines to lower your cholesterol levels but you must not take CRESTOR if you are taking medicines called "statins" or "medicines called beta-blockers".
There are some medicines called "beta-blockers" that reduce the effect of CRESTOR and these medicines are not usually taken more frequently than once every 3 months or every 6 months.
There are some people who may need to take these medicines more than once every 3 months or every 6 months. This may mean that a drug called "statins" will not work for you but will lower your risk of getting any of the conditions you are having.
Your doctor or pharmacist will be helping you to understand this possibility and may tell you to stop taking CRESTOR unless your doctor recommends that you stop taking it.
Do not give this medicine to another person.Taking more than the recommended dose can cause serious side effects.
Immediate action is necessary. Take CRESTOR as your doctor prescribes.
If you do not feel better after taking this medicine, check with your doctor.Your doctor may tell you to take CRESTOR if you are not getting better results from taking it.
If you are not feeling well after taking this medicine, do not take it.
Do not take this medicine if you are angry, have problems with your stomach, you have fever, you have headache or joint pain, you have trouble sleeping, you have muscle weakness or weakness, you have abnormal vision, you are unusually lively or you are unusually grand or grand child.
Stade de France Pharmacy